First Case of Mycobacterium longobardum Infection

Sung Kuk Hong, M.D.1, Ji Yeon Sung, M.D.1, Hyuk Jin Lee, M.D.2, Myung-Don Oh, M.D.3, Sung Sup Park, M.D.1, and Eui-Chong Kim, M.D.1
Departments of Laboratory Medicine1, Orthopedics2, and Internal Medicine3, Seoul National University Hospital, Seoul, Korea

Mycobacterium longobardum is a slow-growing, nontuberculous mycobacterium that was first characterized from the M. terrae complex in 2012. We report a case of M. longobardum induced chronic osteomyelitis. A 71-yr-old man presented with inflammation in the left elbow and he underwent a surgery under the suspicion of tuberculous osteomyelitis. The pathologic tissue culture grew M. longobardum which was identified by analysis of the 65-kDa heat shock protein and full-length 16S rRNA genes. The patient was cured with the medication of clarithromycin and ethambutol without further complications. To the best of our knowledge, this is the first report of a M. longobardum infection worldwide.

Key Words: Mycobacterium longobardum, Nontuberculous mycobacteria, Osteomyelitis

INTRODUCTION

Mycobacterium longobardum is a novel nontuberculous mycobacterium (NTM) that was first characterized as a separate species in 2012 [1]. It was previously included in the M. terrae complex, a classification drafted in the 1970s that included M. nonchromogenicum, M. terrae, and M. triviale. Four new species were then added to this group: M. hiberniae, M. arupense, M. kumamotonense, and M. senuense [2-5]. Despite the fact that the M. terrae complex is ubiquitous in the environment and is generally considered a nonpathogenic NTM [6], M. terrae complex infections affecting the upper extremities and lungs have been continuously reported [7-9]. We report the recovery and identification of M. longobardum from surgically resected tissue of a patient with chronic osteomyelitis.

CASE REPORT

A 71-yr-old man presented with symptoms of pain, redness, and swelling in the left elbow on May 7, 2012. The patient had been previously diagnosed with left elbow bursitis and had undergone surgery to resect the infected tissue at a university hospital in January 2011. At that time, a pathology review of the excised tissue confirmed the diagnosis of tuberculous bursitis with chronic granulomatous inflammation, without isolation of Mycobacterium tuberculosis (MTB). The patient received the antituberculosis drugs of isoniazid, rifampicin, ethambutol, and pyrazinamide for seven months. The patient had a history of being treated for hypertension and diabetes. Physical examination at presentation revealed surgical scarring and tenderness around the left elbow. The patient’s electrolytes, liver function, and complete blood counts were normal. His blood pressure was 107/76 mmHg and his two-hour postprandial glucose level was 106 mg/dL. Magnetic resonance imaging (MRI) of the left elbow revealed localized bone marrow signal alterations at the left ulnar olecranon and substantial effusion with marked synovial hypertrophy in the radiocapitellar joint.

The patient was assessed as having tuberculous osteomyelitis.
according to the history and MRI results. The left elbow was incised and drained using sterilized devices on May 8, 2012. Histological examination of the resected tissue showed necrotizing granulomatous inflammation (Fig. 1). No organisms were detected on Gram or Ziehl-Neelsen staining, and the direct culture of the tissue sample for bacteria was sterile. In addition, there was no evidence of malignancy. The biopsied tissue was cultured for mycobacteria, and mycobacterial growth was observed on Löwenstein-Jensen medium 26 days later. The isolate was acid-fast bacillus and colonies grew rough and unpigmented both in the dark and after light exposure. The mycobacterium was identified as NTM using the Seeplex MTB/NTM ACE Detection Kit (Seegene Inc., Seoul, Korea).

The 16S rRNA gene was sequenced for the NTM identification. The primers and PCR setting used to amplify the target region, the first 500 bp of the 16S rRNA gene, were as previously described [10, 11]. Sequences were analyzed using an ABI PRISM 3730 series DNA Analyzer (Applied Biosystems, Foster City, CA, USA). For the first 500 bp of the 16S rRNA gene sequence, the isolate showed a 98.6% identity match with GenBank sequence JN571166.1 (M. longobardum), a 97.7% identity match with GenBank sequence JN571166.1 (M. terrae), and a 98.4% identity match with GenBank sequence JN571166.1 (M. longobardum) and was classified as M. longobardum (Fig. 2). The primers and PCR settings used to amplify the hsp65 gene were as described previously [13]. Moreover, hsp65 sequencing of the isolate showed a 99.4% match with sequences JN571166.1 (M. longobardum), EF601223.1 (M. terrae), and JX154097.1 (M. terrae). We concluded that the isolate was M. longobardum.

After identifying M. longobardum, the patient was prescribed clarithromycin and ethambutol empirically. The antimicrobial susceptibility test (AST) using the broth microdilution method revealed that the isolate was susceptible to clarithromycin, ethambutol, moxifloxacin, and sulfamethoxazole, but resistant to amikacin, ciprofloxacin, and rifampicin. The therapy was maintained, and the patient was cured without further complications.

**DISCUSSION**

The patient had chronic osteomyelitis due to a M. longobardum infection, which is known to grow rough and unpigmented colonies both in the dark and after light exposure, test positive for nitrate reductase and arylsulfatase, and test negative for niaacin accumulation, Tween 80 hydrolysis, tellurite reduction, urease, and β-glucosidase, as assessed by the analysis of seven isolates stored frozen at -80ºC [1]. However, owing to a lack of clinical reports, there is no information about the pathogenicity or clinical features of M. longobardum. We can deduce the clinical features of M. longobardum from those of the M. terrae complex including M. longobardum, which is known to have low pathogenicity and frequently infects the upper extremities [6, 7].

Accurate identification is important for the treatment of M. terrae complex infection. The present patient was misdiagnosed and initially treated for extrapulmonary tuberculosis. Although
he underwent surgery to resect the infected tissue, he experienced recurrence. A substantial number of patients infected with *M. terrae* also show persistent disease resulting in repeated debridement, tendon extirpation, or amputation due to misdiagnosis and inadequate antibiotic therapy [7].

The isolate was correctly identified after analysis of the *hsp65* and full-length sequences of the 16S rRNA gene of *M. longobardum*, which are unique from those of other species [1]. For specific identification of most mycobacteria, information about the 5’ end of the 16S rRNA gene is sufficient [11]. However, caution should be exercised when interpreting findings using public database references because species may share identical 16S rRNA gene sequences or have intraspecies heterogeneity [11, 14] and insufficient sequence data have been used to compare isolate sequences like those in this newly characterized species. The AST pattern of our isolate was similar to that in the report by Tortoli et al. [1] with the exception of moxifloxacin resistance, in which the AST pattern of *M. longobardum* isolates showed that this species is susceptible to clarithromycin and sulfamethoxazole and resistant to ciprofloxacin, moxifloxacin, linezolid, and streptomycin. According to the AST pattern, a multidrug antibiotic regimen including a macrolide and surgical debridement may still be a useful initial approach to manage patients with *M. longobardum*, similar to those with the *M. terrae* complex [7].

This is the first reported case of *M. longobardum* infection causing chronic osteomyelitis. Proper molecular identification led to a more accurate classification of this organism and an appropriate course of treatment.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Tortoli E, Gitti Z, Klenk HP, Lauria S, Mannino R, Mantegani P, et al. Survey of 150 strains belonging to the *Mycobacterium terrae* complex and description of *Mycobacterium engbaekii* sp. nov., *Mycobacterium heraklionense* sp. nov. and *Mycobacterium longobardum* sp. nov. Int J Syst Evol Microbiol 2013;63:401-11.
2. Cloud JL, Meyer JJ, Pounder JI, Jost KC Jr, Sweeney A, Carroll KC, et al. *Mycobacterium arupense* sp. nov., a non-chromogenic bacterium isolated from clinical specimens. Int J Syst Evol Microbiol 2006;56:1413-8.

3. Kazda J, Cooney R, Monaghan M, Quinn PJ, Stackebrandt E, Dorsch M, et al. *Mycobacterium hiberniae* sp. nov. Int J Syst Bacteriol 1993;43:352-7.

4. Masaki T, Ohkusu K, Hata H, Fujiwara N, Iihara H, Yamada-Noda M, et al. *Mycobacterium kumamotonense* sp. nov. recovered from clinical specimen and the first isolation report of *Mycobacterium arupense* in Japan: novel slowly growing, nonchromogenic clinical isolates related to *Mycobacterium terrae* complex. Microbiol Immunol 2006;50:889-97.

5. Mun HS, Park JH, Kim H, Yu HK, Park YG, Cha CY, et al. *Mycobacterium senuense* sp. nov., a slowly growing, non-chromogenic species closely related to the *Mycobacterium terrae* complex. Int J Syst Evol Microbiol 2008;58:641-6.

6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

7. Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL. *Mycobacterium terrae*: case reports, literature review, and in vitro antibiotic susceptibility testing. Clin Infect Dis 2000;30:444-53.

8. Milne BW, Arnold MH, Hudson B, Coolican MR. Infectious arthritis of the knee caused by *Mycobacterium terrae*: a case report. J Orthop Surg (Hong Kong) 2009;17:103-8.

9. Koh WJ, Choi GE, Lee NY, Shin SJ. Nontuberculous mycobacterial lung disease caused by *Mycobacterium terrae* in a patient with bronchiectasis. Tuberc Respir Dis 2012;72:173-6.

10. Böddinghaus B, Rogall T, Flohr T, Blöcker H, Böttger EC. Detection and identification of mycobacteria by amplification of rRNA. J Clin Microbiol 1990;28:1751-9.

11. Kirschner P, Springer B, Vogel U, Meier A, Wrede A, Kiekenbeck M, et al. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol 1993;31:2882-9.

12. Clinical and Laboratory Standards Institute. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; Approved guideline, MM18-A, Wayne, PA: Clinical and Laboratory Standards Institute, 2008.

13. Kim HY, Kook Y, Yun YJ, Park CG, Lee NY, Shim TS, et al. Proportions of *Mycobacterium massiliense* and *Mycobacterium bolletii* strains among Korean *Mycobacterium chelonae-Mycobacterium abscessus* group isolates. J Clin Microbiol 2008;46:3384-90.

14. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003;16:319-54.